Last reviewed · How we verify
NCT05202275
The Optimization of Antiemetic Regimen for Chemoradiotherapy-induced Nausea and Vomiting (C-RINV) in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCCs): A Prospective Phase Ⅱ Trial
Phase 2 trial testing Olanzapine in Nausea in 43 participants. Status unknown.
1 December 2022
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 1 December 2020 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 September 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Olanzapine (olanzapine) — full drug profile →
Conditions studied
- Nausea — all drugs for Nausea →
- Vomiting — all drugs for Vomiting →
- Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
Sponsor
Chinese Academy of Medical Sciences — full company profile →
Who can join
Adults 18 to 70, any sex, with Nausea or Vomiting. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Nausea-free response rate
Time frame: Up to 6.5 weeks
The percentage of patients with no nausea (Visual Analogue Scale score 0) during concurrent chemotherapy.
Sponsor's own description
This study sought to investigate the efficacy and safety of a three-drug combination antiemetic regimen of olanzapine combined with aprepitant and palonosetron for the prevention of chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05202275
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olanzapine
Trials testing the same drug.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07482891 — An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing · Phase 4 · not yet recruiting
- NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
- NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
- NCT06554613 — Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC · Phase 2 · not yet recruiting
Other recruiting trials for Nausea
Currently open trials in the same condition.
- NCT07378839 — Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting · NA · recruiting
- NCT07523230 — Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department · NA · active not recruiting
- NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
- NCT06954935 — Periorbital Massage for Nausea and Vomiting After Laparoscopic Surgery · NA · recruiting
- NCT06582576 — Mechanisms of Action for the Enterra Medical Gastric Electrical Stimulator · recruiting
Other Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
- NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
- NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
- NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05202275 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
- Last refreshed: 8 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05202275.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing